KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Types and Rates of Major Adverse Cardiovascular Events in Antithrombotic Trials: A Systematic Review and Meta-Analysis.

Yundi Wang, Alejandro Fuerte-Hortigon, Sarvani Chetty, Mays Garah, Robert Sarmiento, Philip A Barber, Gustavo Saposnik, Douglas S Lee, Amit Singnurkar, Richard H Swartz, Joann Varickanickal, Thalia S Field

Can J Cardiol 41(12) 2629-2643

PMID41137817
PMCID-
DOI10.1016/j.cjca.2025.08.358
发表日期2025-10-25
摘要

摘要

BACKGROUND: Major adverse cardiovascular events (MACE) are common composite end points in trials of antithrombotic therapies, yet their definitions and component event rates may vary between cardiovascular disease and stroke populations. We compared definitions and annualized rates of MACE components, bleeding outcomes, and participant demographics in large randomised trials of antithrombotic strategies for secondary prevention in stroke and cardiovascular disease populations, and primary prevention in at-risk individuals. METHODS: We searched Medline (Ovid) for phase III randomised controlled trials of antithrombotic therapies from 2010 to 2024. Eligible studies had ≥ 500 adults and examined antithrombotic interventions for secondary cardio- or cerebrovascular prevention, or primary prevention in at-risk populations, reported ≥ 1 MACE component (stroke, myocardial infarction [MI], mortality), and had ≥ 90 days of follow-up. RESULTS: Of 2075 studies screened, 57 met inclusion criteria (37 cardiovascular and 17 stroke secondary prevention trials, 3 primary prevention trials; 403,957 participants). Stroke rates were higher in stroke than in cardiovascular trials (7.4%/y vs 1.2%/y; P = 0.004), and MI rates were higher in cardiovascular trials (1.5%/y vs 0.1%/y; P < 0.001). Major bleeding and mortality rates were similar across trial types. In meta-regression, annualised stroke and mortality event rates increased with proportion of female participants and decreased with trial follow-up duration. Definitions of MACE and bleeding were variable. CONCLUSIONS: Differences in recurrent event types between stroke and cardiovascular trials suggest that prevention strategies should be disease-specific. Use of standardised MACE and bleeding definitions may improve between-trial comparisons and generalisability to clinical practice. (Major Adverse Cardiovascular Event Types and Rates in Trials of Secondary Stroke Versus General Cardiovascular Prevention Trials. REGISTRATION: PROSPERO CRD42024566128.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。